Table 3. Analysis of subgroups in terms of the risk of gallbladder disease in accordance with the primary variables in tibolone.
| Tibolone use | HR (95% CI) a | P-value |
|---|---|---|
| Tibolone only (without non-MHT) | ||
| Period from menopause to inclusion (years) | ||
| 5~9 | 1.063 (1.003–1.128) | 0.041 |
| 10~ | 1.149 (1.05–1.259) | 0.003 |
| Total period of use (months) | 1.002 (1.001–1.002) | <0.001 |
| Dosage | ||
| 1.25mg | 1.054 (0.858–1.295) | 0.615 |
| Over 5mg | 1.043 (0.468–2.322) | 0.918 |
| Prescribed specialty | ||
| Non-gynecology | 1.042 (0.997–1.09) | 0.07 |
| Dosage of tibolone | ||
| Tibolone 1.25mg vs Non-MHT | 1.315 (1.072–1.614) | 0.009 |
| Tibolone 2.5mg vs Non-MHT | 1.245 (1.215–1.275) | <0.001 |
| Tibolone 5mg vs Non-MHT | 1.117 (0.735–1.697) | 0.606 |
CI, confidence interval; HR, hazard ratio; MHT, menopausal hormone therapy
a HRs were adjusted for age group, body mass index, socioeconic status, region, Charlson comorbidity index, parity, age at menarche, age at menopause, smoking, alcohol, physical exercise, period from menopause to inclusion.